Medical Research

Community information
The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.

Webinars and videos

  • This webinar focuses on new methods and applications in food contamination analysis, bringing together some of the leading experts in food contact materials (FCM) and provides an interactive learning environment for scientists working in this field.

    As food quality and food integrity has become a major topic for the consumer, the penetration path of contaminants in our food chain deriving from the food production and/or the food packaging and storage conditions is gaining attention. Fast and reliable ways of sample preparation and analysis are discussed showing up-to-date examples and how the regulations are applied.
    ** Meet the speakers **

    - Sabrina Moret (Associate Professor, Dept. Food Science, University of Udine)

    - Duncan Goodwin (Director of Technical Services, NSF)

    - Susanne Feifel (Product Group Manager for Kjeldahl, Elemental Analysis and Extraction, BÜCHI)
    ** What will you gain from this webinar? **

    - You will be provided with tangible ways to streamline your sample preparation to detect mineral oil hydrocarbons in cardboard and food as well as bisphenol A in canned food.

    - BUCHI´s solutions for these applications are presented using examples from industry.

    - Furthermore, you will learn about health and safety risks in the field of food packaging and storage. This will be linked to up-to-date information from the leading regulatory authorities.
  • Alongside established drug target classes, innovative approaches are addressing previously undruggable target classes such as protein–protein interactions. This webinar will provide an overview of how compound profiling using the PLA® (Proximity Ligation Assay) technology can be used for in situ analysis of protein interactions by high content screening as part of the Hit-to-Lead workflow, the key advantage being the ability to provide evidence for target engagement of the compound.

    Proximity ligation is a highly specific and sensitive technology to monitor individual proteins, their interactions and post-translational modifications in situ. It provides single molecule resolution and objective and unbiased quantification in cells and tissues on endogenous expression levels.

    Dr. Bernhard Ellinger (Principal Scientist, European ScreeningPort) will describe how the PLA technology has been optimised for use in an automated 384-well screening format with routines for automated image analysis including spot detection, localisation and quantification. He will present a case study of a small molecule drug discovery project performed in collaboration with a biotech partner. The target mechanism involved the disruption of the interaction between amyloid ß oligomers and RAGE (Receptor for Advanced Glycation Endproducts). Profiling of compounds during Hit-to-Lead stages has involved a variety of high content functional cellular assays including PLA. He will discuss the use of PLA in 384-well format as part of a Hit-to-Lead screening cascade to monitor compound-mediated disruption of this receptor-ligand complex.

    Thomas Juehne (Principal Scientist, Sigma-Aldrich) will discuss Duolink®, which is based on the in situ PLA technology, a highly sensitive and selective way of direct in cell visualisation of endogenously expressed proteins and their interacting partners enabling the use of unmodified primary cells.

    The following trademarks are owned by Olink AB: Duolink® and PLA®
  • SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
  • Despite our dependence on cultured cells as models, issues surrounding cell identity, choice of appropriate cell lines, conditions of their growth and storage, microbial contamination and over-passaging are often overlooked or misunderstood. Mistakes can have devastating impacts on the legitimacy and reproducibility of science but potentially also, on careers, reputations and funding streams.

    Topics covered:

    Solutions and options for managing cell culture processes
    The Impact of misidentification
    The international consensus on cell identity and qualification
  • Attend this webinar to discover:

    •Changes to healthcare delivery: hospitals of the future, aging in place, cost of care innovations
    •Role of the patient and consumer influence
    •Role of emerging regions as a consumer and competitor
    •Novel industry business models
    •Key disruptive technologies
  • The truth about delivering clinical research in the UK

    • Are you looking to deliver your research in Europe?
    • Need multiple, reliable sites in each country?
    • Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last five years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research.. This session will be hosted by Jonathan Sheffield, CEO of the NIHR Clinical Research Network. It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    • How much the UK’s market volume of commercial contract research (supported by the NIHR) has changed
    • What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR)
    • On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR support)
    • What percentage of commercial contract studies (supported by the NIHR) are delivered to time and target
    • How the NIHR is keeping clinical research in the public eye
    • How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • The Health Service Journal Clinical Research Impact award winner, Sussex Partnership NHS Foundation Trust, has created an inclusive research network which has given the public, patients, carers and staff the opportunity to learn about and get involved with research in their community.

    Find out why Sussex Partnership were determined to make clinical research everyone’s business and how they implemented their new initiatives.

    This session shares best practice and is aimed at NHS Trusts/primary care practices.
  • Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
  • Frost & Sullivan will provide an outlook for healthcare in 2014 with detailed insights on the regulatory challenges, investment trends, innovation temperature and emerging business models in the Asia-Pacific Healthcare market.
  • M22 - Neue Behandlungsansätze mit IPL und ResurFX-
    Dr. med. Gerd Kautz.
    PB-1005026Rev A
  • During this webinar learn more about unconventional approaches to enhance quality programs with the use of modern handheld technology...

    While regulatory enforcement agencies around the world have increased scrutiny on quality assurance/quality control programs, pharmaceutical manufacturers are increasingly looking for ways to lean out the manufacturing process without compromise to product quality. This push and pull conundrum has manufacturers seeking guidance on global industry regulations while searching for alternatives to legacy quality practices. With the expanding supply chain and the onset of globalization, it is now more important than ever to adjust quality programs to improve efficiency but remain keen on effectiveness for the continued promise of product quality and patient safety.

    Handheld Raman technology is currently being implemented by global pharmaceutical manufacturers and regulatory agencies around the world providing an effective alternative approach to increased testing and heightened quality programs.
  • The key to successful negotiation is preparation and knowledge; these training modules investigate the commercial research environment, delve into the position of the various stakeholder involved and provide both research specific and general negotiation tips to support you in clinical research.

    Module 1: Introduction and life-sciences industry partner
    This module sets the scene for the environment in which commercial clinical research negotiation takes place and considers the importance of maintaining a mutually beneficial partnership approach between the life-sciences industry and the NHS when working together to deliver clinical trials. The latter part of first module goes on to detail the position of the life-sciences industry, from the challenges currently faced to the regulations they must adhere to and the links between specialist budgeting tools and the national costing templates.

    Module 2: Understanding the NHS Organisation’s Position
    This module considers the position of the NHS providing both healthcare to the nation and a commercial research service offering. The session details the currently challenges faced by the NHS, breaks down the national cost template methodology in relation to NHS costs and considers the role of the Government’s national tariff for healthcare.

    Module 3: Negotiation Mediation
    Session three describes the role of the Network as a mediator in commercial trial negotiations. It investigates topics specific to commercial contract research such as the budget confidence, the cost of medicines, set-up fees and alternative costing approaches. Also included are more general tips in relation to negotiating - recognising and handling conflict, building rapport and motivating parties to reach an agreement.

    Together, these modules provide in-depth knowledge around commercial clinical research cost and contract requirements for all parties involved and provide the practical skills to help you be more prepared when negotiation is required.
  • Virtually, all solid dosage forms in the pharmaceutical industry have been manufactured in ‘batch’ despite cost and processing disadvantages associated with manufacturing a product in batch mode. Market forces coupled with a conducive regulatory environment have enabled researchers to consider manufacturing pharmaceuticals ‘continuously’. The presentation addresses the role of material properties in the design of a direct compaction continuous manufacturing system. The presenter believe that a substantial technical challenge to continuous processing is understanding ‘in-process’ material properties , their interaction with process equipment and subsequent effects on product quality.
  • Il Dr.Antonio Rusciani, presenta protocolli di trattamento di lesioni vascolari e profonde del viso e delle gambe con sistema laser Nd:Yag M22.
    PB-1005027Rev A
  • CRISPR endonucleases have recently taken the research world by storm with their elegant and simple mode of RNA-guided gene targeting. CRISPR publications have flooded the literature in recent months, verifying that CRISPR endonucleases can operate via protocols developed for ZFN-based genome editing in human cells, rats, flies, worms, and plants (to name only a few).
  • CRISPR endonucleases have recently taken the research world by storm with their elegant and simple mode of RNA-guided gene targeting. CRISPR publications have flooded the literature in recent months, verifying that CRISPR endonucleases can operate via protocols developed for ZFN-based genome editing in human cells, rats, flies, worms, and plants (to name only a few).
  • This NIHR Clinical Research Network training session will clarify differences between NIHR metrics:

    The NIHR Performance in Initiating and Delivering Clinical Research (70 day benchmark) and the NIHR Clinical Research Network High Level Objectives: a description of purpose, definition and differences.

    The session is designed to support the comparison document that has been recently updated and relaunched. This document can be found in the attachments section of the session.
  • M22 Family- Treatment of superficial thread veins
    Dr. Miguel Montero

    Dr. Miguel Montero explains his methods and techniques for the treatment of Superficial
    Vascular Lesions including Thread veins and Telangiectasia with IPL
    PB-1004993 Ver A
  • This session covers how the NIHR Clinical Research Network can support the medical technology industry in the delivery of clinical research.

    Covering the latest performance data, the session also features the service offerings available free of charge to companies that bring their studies to the UK.
  • Method development and validation are essential parts of the pharmaceutical drug approval process. As process modifications are made and approval criteria become increasingly stringent, changes to the validated method are sometimes necessary. A Quality by Design (QbD) approach to method development uses statistical design of experiments (DoE) to generate a robust method ‘design space’. The design space defines a region in which changes to method parameters will not significantly affect the results, incorporating risk-based assessment of the final method. Rather than developing and validating a single method and proceeding through re-validation as modifications are made, a design space incorporates allowable flexibility into the method.

    A QbD approach is demonstrated here in the development of a stability-indicating method, using UPLC for fast, sensitive separations, and software-driven validation. The flexibility of transferring methods between UPLC and HPLC will also be demonstrated. This streamlined approach to method development affords considerable cost savings as well as a significantly more robust and quality submission to regulatory authorities for faster drug approval.
  • Join a cross-stakeholder panel, including the CEO of, a pharmaceutical industry digital engagement expert and two doctors, to understand areas of mutual interest for doctors engaging with pharma online and the specific types of information and dialogue they are seeking.

    • Are you responsible for advising your organisation on aspects of pharmacy costing for commercial research?
    • Do you know your direct costs from your indirect costs?
    • Want to understand what companies regard as cost of doing business and where this fits in a full cost recovery model?
    • How do we ensure a pragmatic approach to costing to keep companies coming back without undercosting?

    The NIHR Clinical Research Network is hosting a live webinar to talk through the Pharmacy section of the national Industry Costing Template tool, answering these and many other common questions to provide the support you need to gain the full benefits of using this national tool.

    This session will include information regarding the changes introduced in autumn last year, tips on best practice, examples of common queries and dedicated time for your questions with our panel:

    • Anthea Mould, Head of Clinical Support, NIHR Clinical Research Network (Panel Chair)
    • David Leonard, Executive Lead Pharmacist Aseptics & Clinical Trials, Imperial College Healthcare NHS Trust and NPCTAG costing representative
    • Joanna Cantle, Head of Clinical Trials, Pharmacy Department, University Hospitals Southampton and NPCTAG costing representative
    • Laura Bousfield, Industry Costing and Contracts Manager, NIHR Clinical Research Network
  • Cancer stem cells (CSCs), commonly referred to as tumor initiating cells (TICs), are thought to be the origin of replicating malignant cells that remain after the primary tumor is removed or eradicated. While the contribution of TICs to cancers of hematopoietic origin is well established, there is a growing body of evidence that supports the presence of TICs within solid tumors. This heterogeneity contributes to the intrinsic resistance of solid tumors to chemotherapeutics and eventually leads to therapeutic failure and patient death. Historically, screening for oncology directed compounds has been performed in 2-dimensional monolayer cultures which fail to replicate the complex architecture and microenvironment of tumors in vivo. To address this need using prototype manufactured 384-well round bottom clear black plates coated with hydrogel (commonly referred to as ultra-low attachment or ULA plates) we have developed a method to generate single cell type spheroids to accommodate their use in high throughput screening. These cultures were systematically compared to spheres grown in conventional plates and comparative imaging analyses were carried out to assess sphere formation. In addition, using the same plates, we have developed multicellular tumor spheroids (MCTS) composed of various cell types cultured in the same well. Differences in the cellular compositions of these spheroids in response to drugs can be quantified using high content imagers such as the WiScan from Idea-Bio and the High Throughput Flow Cytometer from IntelliCyt. These heterotypic, differentially labeled spheroids are a valuable asset in the generation of cell-based HTS assays capable of identifying molecules that selectively kill TICs and the cells comprising their microenvironment.
  • Learn from industry experts some practices to help better manage the investigation process and how to design processes to minimize unnecessary excursions.

    Microbial excursions as a result of an out of specification result from a quality control test can be time consuming and costly. The investigation of the root cause, analysis of the risk to the product, and determination of corrective/preventative actions take hours of manpower and resources and often are caused by issues around personnel practices, keying errors, and incubation errors.

    Attendees will learn:

    - What is an excursion?
    - How to identify risk in an excursion
    - Tools to help manage the process
  • A guide to using Vitroids from Sigma Aldrich as a tool for achieving laboratory efficiency
  • This 40 minute webinar will focus on the practical laboratory techniques needed to create and validate genetically modified cell lines using CRISPR. A Sigma-Aldrich® technology expert will discuss guidelines and techniques utilized when performing genome editing experiments.
    Topics will include:
    •Transfection of CRISPR reagent into a cell line
    •How to validate the activity level of CRISPR
    •Clonal isolation
    •How to screen clonal populations based on desired modification
  • This 40 minute webinar will focus on the practical laboratory techniques needed to create and validate genetically modified cell lines using CRISPR. A Sigma-Aldrich® technology expert will discuss guidelines and techniques utilized when performing genome editing experiments.
    Topics will include:
    •Transfection of CRISPR reagent into a cell line
    •How to validate the activity level of CRISPR
    •Clonal isolation
    •How to screen clonal populations based on desired modification
  • Telecom companies are increasingly seeking new revenue streams by exploring vertical markets like healthcare. While the industry presents promising opportunities, few telecommunication service providers have been able to establish successful business models in this space.

    Frost & Sullivan will present insights on critical factors that companies overlook while developing their healthcare strategies.
  • The BUCHI M-565 is not just an automated melting point and boiling point product. Several other applications such as slip melting point and melting point ranges can be applied. A guided calibration and verification procedure ensures your results are always accurate.

    During this webinar you will:
    - Learn how automated melting and boiling point determinations are made
    - Discover slip melting point determination of fats and waxes
    - Review melting range determination of semi-crystalline polymers
  • Introduction to “prilling by vibration” will be discussed. Learn how the new BUCHI Encapsulator can immobilize and protect your products, whether you are encapsulating flavored oil or live cells.

    During this webinar you will:
    - Gain an understanding of this technology
    - Learn the benefits of the Encapsulators B-390/B-395 Pro
    - Review the full range of applications
  • This webinar will give an overview of the recently released UK Pharmaceutical and Healthcare Science Society (PHSS) Technical Monograph #20- Bio-contamination, characterization, control, monitoring and deviation management in controlled/ GMP classified areas. The concept of Risk Profiling and Proactive Response (RPPR) to bio-contamination in GMP classified areas, focusing on preventing contamination and not just monitoring for compliance will be presented. How trending environmental monitoring data holistically across all supporting areas can detect an increasing risk of a contamination event in Grade A zones will be examined. In particular, the value of using real-time airborne viable particle detection as part of holistic monitoring strategy for risk escalation will be discussed.

    Many organizations are pro-actively exploring Rapid Microbiological Methods (RMMs). Real-time airborne viable particle counting is an RMM that is generating great interest. The potential opportunities of improved product quality and efficiencies, whilst maintaining patient safety are too significant to ignore. Cases where this technology is providing value today in a pharmaceutical manufacturing environment will be presented. Included will be a brief discussion of critical performance characteristics of real-time viable particle detectors which should be considered when selecting an instrument to monitor GMP classified areas.